Adalimumab Biosimilars in Europe: An Overview of the Clinical Evidence Salvatore BellinviaJ. R. Fraser CummingsChristopher J. Edwards Leading Article 20 May 2019 Pages: 241 - 253
PARP Inhibitors and the Evolving Landscape of Ovarian Cancer Management: A Review Sarah A. CookAnna V. Tinker Review Article 21 March 2019 Pages: 255 - 273
Immunogenicity of Chimeric Antigen Receptor T-Cell Therapeutics Boris GorovitsEugen Koren Review Article 08 May 2019 Pages: 275 - 284
Different Policy Measures and Practices between Swedish Counties Influence Market Dynamics: Part 1—Biosimilar and Originator Infliximab in the Hospital Setting Evelien MoorkensSteven SimoensIsabelle Huys Original Research Article Open access 03 April 2019 Pages: 285 - 297
Different Policy Measures and Practices between Swedish Counties Influence Market Dynamics: Part 2—Biosimilar and Originator Etanercept in the Outpatient Setting Evelien MoorkensSteven SimoensIsabelle Huys Original Research Article Open access 03 April 2019 Pages: 299 - 306
Physicochemical and Biological Characterization of RTXM83, a New Rituximab Biosimilar María L. CeruttiAnalía PesceMauricio Seigelchifer Original Research Article 29 March 2019 Pages: 307 - 319
Assessing Analytical and Functional Similarity of Proposed Amgen Biosimilar ABP 980 to Trastuzumab Katariina M. HuttererAlla PolozovaJennifer Liu Original Research Article Open access 10 April 2019 Pages: 321 - 333
A Global Phase I Clinical Study Comparing the Safety and Pharmacokinetics of Proposed Biosimilar BAT1706 and Bevacizumab (Avastin®) in Healthy Male Subjects Xiaoyun WuChris WynneLi Zhang Original Research Article 23 April 2019 Pages: 335 - 342
Correction to: Vestronidase Alfa: A Review in Mucopolysaccharidosis VII Emma H. McCaffertyLesley J. Scott Correction Open access 16 April 2019 Pages: 343 - 343
